The earnings call reflects a mix of strong leadership transitions, financial stability, and strategic advancements in the clinical pipeline, particularly with COM701 and the TIGIT program. However, these positives are tempered by decreased revenues, increased net losses, and competitive challenges in the market.

Company Guidance

In the recent Compugen Ltd. earnings call for the second quarter of 2025, several key metrics and strategic updates were discussed. The company reported a solid cash position with $93.9 million on hand as of June 30, 2025, and expects a cash runway extending into 2027. Revenues for the quarter were $1.3 million, a decrease from $6.7 million in the same period in 2024, primarily reflecting milestone payments from partnerships with Gilead and AstraZeneca. Research and development expenses were reported at $5.6 million, slightly down from $6.2 million in the previous year, while general and administrative expenses remained stable at $2.2 million. Compugen also highlighted the advancement of its immuno-oncology pipeline, including the dosing of the first patient in its COM701 trial for platinum-sensitive ovarian cancer, with interim analysis expected in the second half of 2026. The company remains focused on its strategic collaborations and anticipates potential milestone payments and tiered royalties from its partnerships, with AstraZeneca estimating peak year revenues of over $5 billion for rilvegostomig.

Leadership Transition

Anat Cohen-Dayag transitions to Executive Chair, focusing on corporate strategy and strategic collaborations, while Eran Ophir takes over as CEO, indicating strong leadership continuity.

Solid Financial Position

Compugen holds $93.9 million in cash with a cash runway expected to last into 2027, providing a stable financial base for future operations.

Advancement of COM701

The first patient was dosed in the MAIA-ovarian trial with plans for interim analysis in 2026, showcasing progress in targeting unmet needs in platinum-sensitive ovarian cancer.

TIGIT Program Developments

AstraZeneca's rilvegostomig, derived from Compugen's COM902, continues to show promise in trials, potentially validating TIGIT antibodies as a drug class.

Partnerships and Milestone Payments

Compugen has received $30.5 million in milestone payments from AstraZeneca and remains eligible for up to $170 million more, indicating strong partnership potential.

Compugen (CGEN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CGEN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.08 / -	0.01	―	―	―
Aug 06, 2025	2025 (Q2)	-0.06 / -0.08	-0.02	-300.00% (-0.06)	―
May 19, 2025	2025 (Q1)	-0.06 / -0.08	-0.08	0.00% (0.00)	―
Mar 04, 2025	2024 (Q4)	0.03 / -0.07	0.11	-163.64% (-0.18)	―
Nov 12, 2024	2024 (Q3)	-0.10 / 0.01	-0.11	109.09% (+0.12)	―
Aug 06, 2024	2024 (Q2)	-0.09 / -0.02	-0.11	81.82% (+0.09)	―
May 20, 2024	2024 (Q1)	-0.11 / -0.08	-0.11	27.27% (+0.03)	―
Mar 05, 2024	2023 (Q4)	0.10 / 0.11	-0.04	375.00% (+0.15)	―
Nov 07, 2023	2023 (Q3)	-0.10 / -0.11	-0.14	21.43% (+0.03)	―
Aug 07, 2023	2023 (Q2)	-0.12 / -0.11	-0.11	0.00% (0.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CGEN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$1.46	$1.46	0.00%
May 19, 2025	$1.39	$1.39	0.00%
Mar 04, 2025	$1.81	$1.68	-7.18%
Nov 12, 2024	$1.74	$1.60	-8.05%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Compugen Ltd (CGEN) report earnings?

Compugen Ltd (CGEN) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Compugen Ltd (CGEN) earnings time?

Compugen Ltd (CGEN) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CGEN EPS forecast?

CGEN EPS forecast for the fiscal quarter 2025 (Q3) is -0.08.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing